Log In
Print this Print this

TG20, Biosimilar rituxan

Also known as: Biosimilar anti-CD20 mAb

  Manage Alerts
Collapse Summary General Information
Company LFB S.A.
DescriptionTransgenically produced CD20 mAb biosimilar
Molecular Target CD20
Mechanism of ActionAntibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentDiscovery
Standard IndicationNon-Hodgkin's lymphoma (NHL)
Indication DetailsTreat non-Hodgkin's lymphoma (NHL)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today